Lesson
See the Infection Inside the Alveolus
CAP reaches distal airspaces, fills alveoli with inflammatory material, disrupts ventilation and diffusion, and can progress from a focal lung process to respiratory failure, sepsis, or metastatic infection.
- Alveoli
- Gas exchange
- Typical pathogens
- Atypical pathogens
- Viral coinfection
A pathogen reaches an alveolar compartment.
Cells and fluid reduce effective ventilation.
Perfusion continues through poorly ventilated units.
Hypoxemia, organ injury, or sepsis can follow.
Start with physiology
Consolidated airspaces ventilate poorly while perfusion continues, producing mismatch, hypoxemia, increased work, and reduced reserve.
Keep pathogen groups distinct
S. pneumoniae and H. influenzae remain typical targets. Mycoplasma, Chlamydia pneumoniae, and Legionella are not reliably covered by beta-lactams.
Include viruses
Influenza, RSV, SARS-CoV-2, and other viruses can cause CAP. A positive virus can explain disease, coexist with bacteria, or represent detection without full causal certainty.
Let the host change risk
Age, pregnancy, cardiopulmonary disease, renal or hepatic disease, diabetes, alcoholism, malignancy, asplenia, immune status, aspiration, and prior microbiology alter both severity and selection.
Quick check
Lesson
Require a Compatible Syndrome and New Infiltrate
Cough, dyspnea, pleuritic pain, fever, tachypnea, hypoxemia, and focal findings can suggest CAP, but adult guideline treatment begins with clinical and imaging evidence rather than cough or sputum color alone.
- Clinical syndrome
- New infiltrate
- Chest radiograph
- Lung ultrasound
- Alternative diagnoses
Cough, dyspnea, fever, pain, and trajectory raise suspicion.
Vitals, oxygen, work, perfusion, and mentation define consequence.
Radiograph or expert ultrasound supports adult CAP.
Embolism, edema, aspiration, and chronic infection can mimic it.
Confirm lower-airway disease
Acute bronchitis, asthma, COPD, heart failure, pulmonary embolism, malignancy, tuberculosis, and endemic fungi can resemble CAP.
Use imaging to confirm
Chest radiography remains widely available. The 2025 ATS update accepts lung ultrasound as an alternative where acquisition and interpretation expertise exist.
Respect technical limits
Obesity, wounds, drains, positioning, or concern for embolism or malignancy can make ultrasound incomplete and require another modality.
Do not overtrust procalcitonin
An initial low result does not reliably exclude bacterial CAP. Use biomarkers inside the full syndrome, imaging, severity, microbiology, and trajectory.
Quick check
Lesson
Treat Disposition as a Clinical Intervention
Where treatment occurs determines monitoring, route, rescue capability, and time to escalation. PSI supports hospitalization decisions, while severe CAP requires one major criterion or at least three minor criteria.
- Pneumonia Severity Index
- Major criteria
- Minor criteria
- ICU intensity
- Social safety
A validated rule supports mortality and site decisions.
Ventilation or vasopressor shock defines severe CAP.
Three or more establish severe disease.
Intake, support, access, oxygen, and goals still matter.
Use PSI with judgment
The 2019 guideline prefers PSI over CURB-65 for hospitalization support, but no score can guarantee a safe home plan.
Recognize a major criterion
Mechanical ventilation or septic shock requiring vasopressors establishes severe CAP without waiting for additional criteria.
Count minor criteria correctly
Respiratory rate at least 30, P/F ratio at most 250, multilobar disease, confusion, uremia, leukopenia, thrombocytopenia, hypothermia, and hypotension requiring aggressive fluids form the validated set.
Protect delivery outside the hospital
Swallowing, cognition, housing, caregiver support, pharmacy access, oxygen, and follow-up can override a numerically low mortality estimate.
Quick check
Lesson
Order a Test Only When Someone Owns the Result
Routine cultures are low yield in uncomplicated outpatient disease. Severe CAP, validated resistant-pathogen risk, intubation, treatment failure, or a specific epidemiologic question creates a stronger reason to test.
- Respiratory culture
- Blood culture
- MRSA nasal PCR
- Urinary antigen
- Influenza molecular test
Severe or resistant-risk disease supports cultures.
A detected organism is not automatically causal.
Validated MRSA screening can support de-escalation.
Every pending test needs a reviewer and decision.
Target bacterial cultures
Obtain respiratory and blood cultures in severe CAP and selected resistant-pathogen or failure settings. Colonization and poor specimens can mislead.
Use MRSA nasal testing mainly to de-escalate
A negative validated test often has strong negative predictive value. A positive test alone does not prove MRSA pneumonia.
Target urinary antigens
Legionella and pneumococcal urinary antigen testing fits severe disease or specific epidemiology rather than every outpatient.
Use molecular influenza testing
During community circulation, rapid molecular testing is preferred over rapid antigen testing and can change antiviral and infection-control decisions.
Quick check
Lesson
Match Outpatient Spectrum to Comorbidity and Safety
Healthy adults without listed comorbidities or resistant-pathogen risk can receive high-dose amoxicillin or doxycycline. Macrolide monotherapy depends on low local pneumococcal resistance. Comorbidity broadens the supported regimen set.
- Amoxicillin
- Doxycycline
- Macrolide threshold
- Combination therapy
- Respiratory fluoroquinolone
Amoxicillin or doxycycline can fit.
Monotherapy needs a low local rate.
Use combination therapy or a selected respiratory quinolone.
Allergy, QT, organs, interactions, and access choose the path.
Use focused healthy-outpatient options
The 2019 regimen lists amoxicillin 1 g three times daily or doxycycline 100 mg twice daily. Macrolide monotherapy is conditional on local pneumococcal resistance below 25 percent.
Broaden with defined comorbidity
Chronic heart, lung, liver, or renal disease, diabetes, alcoholism, malignancy, or asplenia supports beta-lactam plus macrolide or doxycycline, or respiratory fluoroquinolone monotherapy.
Audit the QT stack
Macrolides and respiratory fluoroquinolones can add repolarization risk. Review QTc, potassium, magnesium, bradycardia, cardiac disease, antipsychotics, antiarrhythmics, and interactions.
Reserve class risk intentionally
Fluoroquinolone convenience does not erase tendon, nerve, CNS, glucose, QT, aortic, and C. difficile harms. Document why benefit outweighs safer alternatives.
Quick check
Lesson
Build the Inpatient Regimen Around Severity
Nonsevere inpatient CAP commonly uses a beta-lactam plus macrolide or respiratory fluoroquinolone. Severe CAP uses beta-lactam plus macrolide or beta-lactam plus respiratory fluoroquinolone, not fluoroquinolone monotherapy.
- Nonsevere regimen
- Severe regimen
- Atypical coverage
- IV to oral
- Aspiration boundary
Beta-lactam plus macrolide is a standard frame.
Beta-lactam plus macrolide or respiratory quinolone is required.
Current stability and absorption control route.
Aspiration alone does not prove abscess or empyema.
Use a complete nonsevere regimen
Ceftriaxone, cefotaxime, ampicillin-sulbactam, or another supported beta-lactam is paired with macrolide. Beta-lactam plus doxycycline is an alternative when both macrolides and fluoroquinolones are unsuitable.
Prescribe a complete adult exposure
Common guideline doses include ampicillin-sulbactam 1.5 to 3 g IV every 6 hours, cefotaxime 1 to 2 g IV every 8 hours, ceftriaxone 1 to 2 g IV daily, or ceftaroline 600 mg IV every 12 hours, paired with azithromycin 500 mg daily or clarithromycin 500 mg twice daily. Nonsevere monotherapy options include levofloxacin 750 mg daily or moxifloxacin 400 mg daily. Adjust for organ function, interactions, patient factors, and current local protocol.
Use combination therapy in severe disease
A beta-lactam plus macrolide or respiratory fluoroquinolone provides the supported severe-CAP frame. Monotherapy is inadequate for this severity tier.
Transition by physiology
Move from IV to oral when hemodynamics, oxygenation, mentation, intake, and gastrointestinal function support dependable exposure, not simply after a fixed number of doses.
Avoid routine extra anaerobic coverage
Suspected aspiration does not automatically require clindamycin or metronidazole. Add anaerobic treatment when abscess, empyema, or another defined source supports it.
Quick check
Lesson
Replace Broad Labels With Validated Risk
The retired healthcare-associated pneumonia category promoted unnecessary broad therapy. Prior respiratory isolation and recent hospitalization with parenteral antibiotics are more specific MRSA and Pseudomonas signals.
- Prior isolation
- Recent IV antibiotics
- MRSA coverage
- Antipseudomonal beta-lactam
- De-escalation
Respiratory MRSA or Pseudomonas history changes risk.
A 90-day exposure strengthens concern.
Microbiology makes later narrowing possible.
A reasonable start still needs an exit.
Add MRSA therapy for a reason
Vancomycin or linezolid can be added when validated risk, severe post-influenza necrotizing disease, or local evidence supports it.
Cover Pseudomonas through a complete regimen
Use an active antipseudomonal beta-lactam selected from prior susceptibility and local data, while preserving the rest of the CAP regimen and obtaining cultures.
Do not combine beta-lactams casually
Two agents from the same broad structural class rarely solve the intended dual-coverage question and can add harm without complementary activity.
Own de-escalation
A reasonable empiric start creates an obligation to review cultures, MRSA testing, susceptibility, clinical response, and alternative diagnoses promptly.
Quick check
Lesson
Show Where ATS and IDSA Disagree
The 2025 ATS update and IDSA agree that virus-positive outpatients without comorbidity and low bacterial suspicion can avoid empiric antibiotics, and that severe hospitalized CAP should receive them. They disagree on routine treatment for comorbid outpatients and nonsevere inpatients.
- Positive viral test
- Bacterial coinfection
- ATS position
- IDSA position
- Conditional evidence
Virus-positive disease can avoid antibiotics when bacterial suspicion is low.
Empiric antibacterial therapy remains appropriate.
ATS favors treatment while IDSA rejects a routine default.
ATS favors treatment while IDSA favors dynamic individualization.
Preserve the shared ground
ATS conditionally suggests no empiric antibiotics for virus-positive outpatients without comorbidity when bacterial suspicion is low. Severe CAP still receives empiric antibacterial therapy.
State the ATS recommendation
ATS conditionally suggests antibiotics for virus-positive outpatients with comorbidity and virus-positive nonsevere inpatients because of coinfection concern.
State the IDSA objection
IDSA rejected those two defaults, arguing that bacterial coinfection is often overestimated and that nonsevere disease permits dynamic individualized reassessment.
Do not pretend certainty
Evidence quality is very low. The correct educational response is to show the conflict, not hide it under one universal algorithm.
Quick check
Lesson
Let Clinical Stability Control the Exit
The 2025 ATS update permits treatment shorter than five days, with a minimum of three days, for stable outpatients and stable nonsevere inpatients. Severe CAP receives at least five days, and complications or resistant pathogens often require more.
- Clinical stability
- Minimum three days
- Severe minimum
- Complications
- Follow-up imaging
Vitals, oxygen, mentation, and intake must recover.
Selected stable nonsevere adults may stop before day five.
Necrosis, resistant pathogens, or deep infection need more.
Reopen diagnosis, delivery, organism, and source control.
Define stability completely
Resolution of vital-sign abnormalities, adequate oxygenation, normal mentation, and ability to eat are central. One improved fever does not establish stability.
Use the short-course update narrowly
Less than five days is conditional, begins at a minimum of three days, and weakens with severe disease, necrosis, dense burden, bronchiectasis, pregnancy, recent antibiotics, resistant pathogens, or poor response.
Extend for the biology
Severe CAP, S. aureus, Pseudomonas, empyema, abscess, bacteremia, meningitis, endocarditis, or another deep focus requires a different duration and source-control plan.
Avoid automatic repeat imaging
Promptly resolved symptoms do not require routine follow-up imaging. Persistent symptoms, recurrence, hemoptysis, weight loss, smoking history, or malignancy concern creates a defined question.
Quick check
Lesson
Close the CAP System
A high-quality CAP plan is reconstructable from diagnosis through prevention. Pediatric disease and pleural complications require age-specific sources rather than adult-regimen extrapolation.
- Complete plan
- Pediatric boundary
- Pleural ultrasound
- Vaccination
- Recurrence prevention
Dose, route, safety, monitoring, and exit are explicit.
Children require age-specific evidence and protocols.
Reconcile influenza, pneumococcal, and COVID-19 protection.
Response, recurrence, and imaging questions reach someone.
Respect pediatric scope
The 2026 IDSA and PIDS update currently focuses on parapneumonic effusion and empyema. It does not justify applying adult regimens to children or claiming every pediatric CAP question is newly updated.
Characterize pleural fluid efficiently
For a child with radiographic moderate or large effusion, chest ultrasound is preferred over routine CT or MRI to define size and complexity.
Connect prevention
Reconcile influenza, pneumococcal, COVID-19, and age or risk-based vaccines after stabilization. Address tobacco, swallowing, aspiration, alcohol, mobility, and access.
Teach the full exit
Explain expected response, adverse effects, missed doses, urgent breathing or neurologic changes, failure criteria, follow-up owner, and when a new evaluation is needed.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 172 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- ATS Diagnosis and Management of Community-Acquired Pneumonia, 2025
- IDSA Position Statement on the 2025 CAP Update
- ATS and IDSA Adult CAP Guideline, 2019
- IDSA and PIDS Pediatric CAP Update, 2026
- CDC Pneumonia Management and Prevention Guidelines
- FDA Fluoroquinolone Safety Communication
- FDA Fluoroquinolone Aortic Risk Communication